FARE Blog

Today, Food and Drug Administration (FDA) panelists voted to recommend the approval of Aimmune Therapeutics’ groundbreaking peanut allergy treatment, AR101, for patients aged 4-17.

On Friday, September 13, the Food and Drug Administration (FDA) will hold an advisory committee meeting to review and make recommendations on the safety and effectiveness of Aimmune Therapeutics’ groundbreaking peanut allergy treatment, AR101.

As the food allergy community awaits Food and Drug Administration approval of two possible treatments for peanut allergy – Aimmune’s AR101 peanut oral immunotherapy product and DBV’s Viaskin Peanut patch for epicutaneous (“on the skin”) immunotherapy – a third approach to peanut allergy treatment made news this week.

More than 32 million people have food allergies. Treatments and a cure will be found the same way they’re found for other major diseases—through research.

As I enter my final year of high school, I continue to be severely allergic to peanuts, tree nuts, eggs, dairy, all legumes, mustard and soy. I have had about seven anaphylactic reactions throughout my youth, my first at the age of 13. Since then I have learned my telltale symptoms and take every precaution under the sun to avoid my allergens and future reactions.

As the number of people with food allergies skyrockets, the federal government is falling behind. Food allergy research is among the lowest funded of all major diseases.

Elizabeth’s five-month-old daughter Carly was diagnosed as a newborn with allergies to milk and soy. Here Elizabeth tells how Carly has benefited from nutritional intervention following her diagnosis.

Your high school student with food allergies will soon head off to college. How will they find the accommodations they need, and what can they safely eat? Find answers to your college dining questions in a July 2019 webinar now available on foodallergy.org.

I graduated from high school this past May, and I am so excited to start my next adventure – college life! I am headed away from home and will live on campus, which is another exciting adventure, but it is also really scary.

In a FARE-funded study published in the prestigious journal Science, researchers at Yale University and other institutions report the discovery of a subset of immune cells that is important in anaphylaxis, a severe and potentially life-threatening allergic reaction.